Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: Preservation of in vitro function

Vox Sanguinis

Volumn 108, Issue 4, 2015, Pages 340-349

  Sandgren, P ^a   Diedrich, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

UVA; Amotosalen; Pathogen inactivation; Platelets

Indexed keywords

AMOTOSALEN; CD31 ANTIGEN; CD40 LIGAND; DOUBLE DOSE BUFFY COAT PLATELET CONCENTRATE; DUAL SPECIFICITY PHOSPHATASE 2; GLYCOPROTEIN IB ALPHA; PADGEM PROTEIN; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG; FUROCOUMARIN DERIVATIVE; PHOTOSENSITIZING AGENT;

ARTICLE; BLOOD TRANSFUSION DEVICE; CONTROLLED STUDY; IN VITRO STUDY; INSTRUMENT STERILIZATION; MEDICAL DEVICE; MITOCHONDRIAL MEMBRANE POTENTIAL; PHOTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRAVIOLET A RADIATION; BLOOD SAFETY; DRUG EFFECTS; HUMAN; METABOLISM; MICROBIOLOGY; PROCEDURES; RADIATION RESPONSE; THROMBOCYTE; ULTRAVIOLET RADIATION;

BLOOD PLATELETS; BLOOD SAFETY; FUROCOUMARINS; HUMANS; PHOTOSENSITIZING AGENTS; ULTRAVIOLET RAYS;

EID: 84927911609     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12232     Document Type: Article

References (63)

1. Grass JA, Wafa T, Reames A, et al.: Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 9:3140-3147
2. Nussbaumer W, Allerstorfer D, Grabmer C, et al.: Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods. Transfusion 2007; 7:1125-1133
3. Irsch J, Lin L: Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 2011; 1:19-31
4. Zeddies S, De Cuyper IM, van der Meer PF, et al.: Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014; 54:2292-300
5. Mohr H, Gravemann U, Bayer A, et al.: Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009; 9:1956-1963
6. Mohr H, Steil L, Gravemann U, et al.: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 12:2612-2624
7. Prowse CV: Component pathogen inactivation: a critical review. Vox Sang 2013; 3:183-199
8. Coene J, Devreese K, Sabot B, et al.: Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion 2014; 5:1321-1331
9. Feys HB, Van Aelst B, Devreese K, et al.: Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Vox Sang 2014; 4:307-315
10. Chavarin P, Cognasse F, Argaud C, et al.: In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System). Vox Sang 2011; 2:247-249
11. van Rhenen DJ, Vermeij J, Mayaudon V, et al.: Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 4:206-214
12. Janetzko K, Cazenave JP, Kluter H, et al.: Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 9:1443-1452
13. McCullough J, Vesole DH, Benjamin RJ, et al.: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 5:1534-1541
14. van Rhenen D, Gulliksson H, Cazenave JP, et al.: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 6:2426-2433
15. Hechler B, Ohlmann P, Chafey P, et al.: Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013; 6:1187-1200
16. Picker SM, Schneider V, Oustianskaia L, et al.: Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009; 11:2311-2318
17. Vanderlinde RE: Measurement of total lactate dehydrogenase activity. Ann Clin Lab Sci 1985; 1:13-31
18. Bertolini F, Murphy S: A multicenter evaluation of reproducibility of swirling in platelet concentrates. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Transfusion 1994; 9:796-801
19. Moroff G, Eich J, Dabay M: Validation of use of the Nageotte hemocytometer to count low levels of white cells in white cell-reduced platelet components. Transfusion 1994; 1:35-38
20. VandenBroeke T, Dumont LJ, Hunter S, et al.: Platelet storage solution affects on the accuracy of laboratory tests for platelet function: a multi-laboratory study. Vox Sang 2004; 3:183-188
21. Lundin A: Use of firefly luciferase in ATP-related assays of biomass, enzymes, and metabolites. Methods Enzymol 2000; 305:346-370
22. Bennett JS, Shattil SJ, Power JW, et al.: Interaction of fibrinogen with its platelet receptor. Differential effects of alpha and gamma chain fibrinogen peptides on the glycoprotein IIb-IIIa complex. J Biol Chem 1988; 263:12948-12953
23. Sandgren P, Meinke S, Eckert E, et al.: Random aggregates in newly produced platelet units are associated with platelet activation and release of the immunomodulatory factors sCD40L and RANTES. Transfusion 2013; 54:602-612
24. Sandgren P, Saeed K: Storage of buffy-coat-derived platelets in additive solution: in vitro effects on platelets of the air bubbles and foam included in the final unit. Blood Transfus 2011; 2:182-188
25. Sandgren P, Stjepanovic A: High-yield platelet units revealed immediate pH decline and delayed mitochondrial dysfunction during storage in 100% plasma as compared with storage in SSP+. Vox Sang 2012; 1:55-63
26. Gulliksson H: Defining the optimal storage conditions for the long-term storage of platelets. Transfus Med Rev 2003; 3:209-215
27. Zhang JG, Carter CJ, Culibrk B, et al.: Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma. Transfusion 2008; 5:847-856
28. Apelseth TO, Bruserud O, Wentzel-Larsen T, et al.: In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 4:653-665
29. Apelseth TO, Hervig T: In vitro evaluation of platelet concentrates during storage: platelet counts and markers of platelet destruction. Transfus Apher Sci 2007; 3:261-268
30. Fijnheer R, Modderman PW, Veldman H, et al.: Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage. Transfusion 1990; 1:20-25
31. Fijnheer R, Pietersz RN, de Korte D, et al.: Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. Transfusion 1990; 7:634-638
32. Holme S, Sweeney JD, Sawyer S, et al.: The expression of p-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997; 1:12-17
33. Cognasse F, Boussoulade F, Chavarin P, et al.: Release of potential immunomodulatory factors during platelet storage. Transfusion 2006; 7:1184-1189
34. Fullard JF: The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004; 14:1567-1576
35. Khan SY, Kelher MR, Heal JM, et al.: Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006; 7:2455-2462
36. Shattil SJ: Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost 1995; 1:149-155
37. Johnson L, Loh YS, Kwok M, et al.: In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system. Transfus Med 2013; 23:121-129
38. Picker SM, Speer R, Gathof BS: Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004; 3:320-329
39. Holme S, Heaton WA, Courtright M: Platelet storage lesion in second-generation containers: correlation with platelet ATP levels. Vox Sang 1987; 4:214-220
40. Kilkson H, Holme S, Murphy S: Platelet metabolism during storage of platelet concentrates at 22 degrees C. Blood 1984; 2:406-414
41. Holme S: Storage and quality assessment of platelets. Vox Sang 1998; 2:207-216
42. Berndt MC, Shen Y, Dopheide SM, et al.: The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001; 1:178-188
43. Henrita van Zanten G, Saelman EU, Schut-Hese KM, et al.: Platelet adhesion to collagen type IV under flow conditions. Blood 1996; 10:3862-3871
44. White JG, Krumwiede MD, Escolar G: Glycoprotein Ib is homogeneously distributed on external and internal membranes of resting platelets. Am J Pathol 1999; 6:2127-2134
45. Falati S, Patil S, Gross PL, et al.: Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 2006; 2:535-541
46. Sandgren P, Larsson S, Wai-San P, et al.: The effects of pneumatic tube transport on fresh and stored platelets in additive solution. Blood Transfus 2014; 1:85-90
47. Cazenave JP, Aleil B, Wiesel ML, et al.: In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen. Vox Sang 2004; 3:201-202
48. Knutson F, Alfonso R, Dupuis K, et al.: Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000; 4:209-216
49. Fong KP, Barry C, Tran AN, et al.: Deciphering the human platelet sheddome. Blood 2011; 1:15-26
50. Semple JW, Italiano JE Jr, Freedman J: Platelets and the immune continuum. Nat Rev Immunol 2011; 4:264-274
51. Cognasse F, Osselaer JC, Payrat JM, et al.: Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion 2008; 5:809-813
52. Sandgren P, Shanwell A, Gulliksson H: Storage of buffy coat-derived platelets in additive solutions: in vitro effects of storage at 4 degrees C. Transfusion 2006; 5:828-834
53. Shanwell A, Falker C, Gulliksson H: Storage of platelets in additive solutions: the effects of magnesium and potassium on the release of RANTES, beta-thromboglobulin, platelet factor 4 and interleukin-7, during storage. Vox Sang 2003; 3:206-212
54. Stack G, Snyder EL: Cytokine generation in stored platelet concentrates. Transfusion 1994; 1:20-25
55. Chicheportiche Y, Bourdon PR, Xu H, et al.: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 51:32401-32410
56. Henn V, Slupsky JR, Grafe M, et al.: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 6667:591-594
57. Phipps RP, Koumas L, Leung E, et al.: The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis. Curr Opin Investig Drugs 2001; 6:773-777
58. Zhang W, Huang W, Jing F: Contribution of blood platelets to vascular pathology in Alzheimer's disease. J Blood Med 2013; 4:141-147
59. Shanwell A, Diedrich B, Falker C, et al.: Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days. Transfusion 2006; 6:973-979
60. Larsson S, Sandgren P, Sjodin A, et al.: Automated preparation of platelet concentrates from pooled buffy coats: in vitro studies and experiences with the OrbiSac system. Transfusion 2005; 5:743-751
61. Gulliksson H, AuBuchon JP, Cardigan R, et al.: Storage of platelets in additive solutions: a multicentre study of the in vitro effects of potassium and magnesium. Vox Sang 2003; 3:199-205
62. Gulliksson H, AuBuchon JP, Vesterinen M, et al.: Storage of platelets in additive solutions: a pilot in vitro study of the effects of potassium and magnesium. Vox Sang 2002; 3:131-136
63. Gulliksson H, Sandgren P, Sjodin A, et al.: Storage of platelets: effects associated with high platelet content in platelet storage containers. Blood Transfus 2012; 2:205-212